Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast
- 30 June 2010
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 88 (2) , 223-230
Abstract
According to available information, montelukast is metabolized by cytochrome P450 (CYP) 3A4 and 2C9. In order to study the significance of CYP2C8 in the pharmacokinetics of montelukast, 10 healthy subjects were administered gemfibrozil 600 mg or placebo twice daily for 3 days, and 10 mg montelukast on day 3, in a randomized, crossover study. Gemfibrozil increased the mean area under the plasma concentration–time curve (AUC)0–∞, peak plasma concentration (Cmax), and elimination half‐life (t1/2) of montelukast 4.5‐fold, 1.5‐fold, and 3.0‐fold, respectively (P < 0.001). After administration of gemfibrozil, the time to reach Cmax (tmax) of the montelukast metabolite M6 was prolonged threefold (P = 0.005), its AUC0–7 was reduced by 40% (P = 0.027), and the AUC0–24 of the secondary metabolite M4 was reduced by >90% (P < 0.001). In human liver microsomes, gemfibrozil 1‐O‐β glucuronide inhibited the formation of M6 (but not of M5) from montelukast 35‐fold more potently than did gemfibrozil (half‐maximal inhibitory concentration (IC50) 3.0 and 107 µmol/l, respectively). In conclusion, gemfibrozil markedly increases the plasma concentrations of montelukast, indicating that CYP2C8 is crucial in the elimination of montelukast. Clinical Pharmacology & Therapeutics (2010) 88 2, 223–230. doi: 10.1038/clpt.2010.73Keywords
This publication has 30 references indexed in Scilit:
- Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible InhibitionChemical Research in Toxicology, 2009
- Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor responsePharmacogenetics and Genomics, 2009
- Determinants of Cytochrome P450 2C8 Substrate BindingJournal of Biological Chemistry, 2008
- Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and NateglinideThe Journal of Clinical Pharmacology, 2008
- Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humansBritish Journal of Clinical Pharmacology, 2007
- SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKASTDrug Metabolism and Disposition, 2005
- Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjectsBritish Journal of Clinical Pharmacology, 2005
- Lipid-lowering response to statins is affected by CYP3A5 polymorphismPharmacogenetics, 2004
- A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonistJournal of Allergy and Clinical Immunology, 1998
- Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1996